<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03256045</url>
  </required_header>
  <id_info>
    <org_study_id>9757</org_study_id>
    <secondary_id>NCI-2017-00453</secondary_id>
    <secondary_id>9757</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT03256045</nct_id>
  </id_info>
  <brief_title>Panobinostat, Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>CLBH589DUS108T: Panobinostat With Carfilzomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Correlation With In Vitro Chemosensitivity Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well panobinostat, carfilzomib and dexamethasone work in
      treating patients with multiple myeloma that has come back or does not respond to treatment.
      Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for
      cell growth. Drugs used in chemotherapy, such as carfilzomib and dexamethasone, work in
      different ways to stop the growth of cancer cells, either by killing the cells, by stopping
      them from dividing, or by stopping them from spreading. Using multiple myeloma cells from
      patients' blood samples, the researchers will do laboratory tests to look at how well each of
      the drugs, alone and in different combinations, kill multiple myeloma cells. If the
      laboratory tests work well, they may be used in the future to help plan treatment for future
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To correlate in vitro drug sensitivity testing with clinical response by determining the
      rate of in vitro drug sensitivity to panobinostat, carfilzomib, and dexamethasone singly and
      in combination, doublets and triplets.

      SECONDARY OBJECTIVES:

      I. To monitor response rates (partial response [PR], very good partial response [VGPR], and
      complete response) using the International Myeloma Working Group Uniform Response Criteria
      for Multiple Myeloma.

      TERTIARY OBJECTIVES:

      I. Progression free survival and overall survival will be assessed for up to 3 years after
      last dose.

      OUTLINE:

      Patients receive panobinostat orally (PO) on days 1, 3, 5, 15, 17, and 19. Patients also
      receive carfilzomib intravenously (IV) and dexamethasone PO on days 1, 2, 8, 9, 15, and 16.
      Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or
      unacceptable toxicity. Patients also undergo collection of blood and/or bone marrow samples
      for testing via in vitro chemosensitivity assay.

      After completion of study treatment, patients are followed up every 3 months for up to 3
      years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 31, 2018</start_date>
  <completion_date type="Anticipated">May 16, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 16, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Partial response (PR) rate</measure>
    <time_frame>Up to 3 years after last study treatment</time_frame>
    <description>Assessed using the International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Very good partial response (VGPR) rate</measure>
    <time_frame>Up to 3 years after last study treatment</time_frame>
    <description>Assessed using the International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Response (CR) rate</measure>
    <time_frame>Up to 3 years after last study treatment</time_frame>
    <description>Assessed using the International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of multiple myeloma cells in-vitro drug sensitivity to Panobinostat</measure>
    <time_frame>At baseline</time_frame>
    <description>The half maximal inhibitory concentration (IC50) will be generated in vitro.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of multiple myeloma cells in-vitro drug sensitivity to Carfilzomib</measure>
    <time_frame>At baseline</time_frame>
    <description>The half maximal inhibitory concentration (IC50) will be generated in vitro.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of multiple myeloma cells in-vitro drug sensitivity to Dexamethasone</measure>
    <time_frame>At baseline</time_frame>
    <description>The half maximal inhibitory concentration (IC50) will be generated in vitro.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of multiple myeloma cells in-vitro drug sensitivity to Carfilzomib and Panobinostat in combination</measure>
    <time_frame>At baseline</time_frame>
    <description>The half maximal inhibitory concentration (IC50) will be generated in vitro.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of multiple myeloma cells in-vitro drug sensitivity to Dexamethasone Panobinostat in combination</measure>
    <time_frame>At baseline</time_frame>
    <description>The half maximal inhibitory concentration (IC50) will be generated in vitro.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of multiple myeloma cells in-vitro drug sensitivity to Carfilzomib and Dexamethasone in combination</measure>
    <time_frame>At baseline</time_frame>
    <description>The half maximal inhibitory concentration (IC50) will be generated in vitro.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of multiple myeloma cells in-vitro drug sensitivity to Panobinostat, Carfilzomib and Dexamethasone in combination</measure>
    <time_frame>At baseline</time_frame>
    <description>The half maximal inhibitory concentration (IC50) will be generated in vitro.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 3 years after last study treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 3 years after last study treatment</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Recurrent Plasma Cell Myeloma</condition>
  <condition>Refractory Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment (panobinostat, carfilzomib, dexameth, chemo assay)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19. Patients also receive carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (panobinostat, carfilzomib, dexameth, chemo assay)</arm_group_label>
    <other_name>Kyprolis</other_name>
    <other_name>PR-171</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chemosensitivity Assay</intervention_name>
    <description>Undergo in vitro chemosensitivity testing</description>
    <arm_group_label>Treatment (panobinostat, carfilzomib, dexameth, chemo assay)</arm_group_label>
    <other_name>Chemosensitivity Testing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (panobinostat, carfilzomib, dexameth, chemo assay)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (panobinostat, carfilzomib, dexameth, chemo assay)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panobinostat</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (panobinostat, carfilzomib, dexameth, chemo assay)</arm_group_label>
    <other_name>Faridak</other_name>
    <other_name>Farydak</other_name>
    <other_name>LBH589</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of multiple myeloma refractory to or relapsed after &gt;= 1 line of prior
             therapy (International Myeloma Working Group [IMWG] criteria)

          -  Measurable disease, as indicated by one of the following:

               -  Serum monoclonal (M)-protein &gt;= 1.0 g/dL

               -  Elevated free light chain as per IMWG criteria, and abnormal ratio

               -  Urine Bence Jones protein &gt; 200 mg/24 hr

          -  Absolute neutrophil count (ANC) of &gt;= 1,000/uL

          -  Platelet count of &gt;= 100,000/uL

          -  Hemoglobin &gt;= 7 g/dL

          -  Creatinine =&lt; 2.0 mg/dL or calculated creatinine clearance &gt;= 30 mL/min

          -  Total bilirubin =&lt; upper limit of normal (ULN) unless elevation is thought to be due
             to Gilbert's syndrome

          -  Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and
             serum glutamate pyruvate transaminase (SPGT) (alanine aminotransferase [ALT]) =&lt; ULN

          -  Serum sodium within normal limits or corrected to within normal limits with
             supplements before starting treatment

          -  Potassium within normal limits or corrected to within normal limits with supplements
             before starting treatment

          -  Magnesium within normal limits or corrected to within normal limits with supplements
             before starting treatment

          -  Phosphorus within normal limits or corrected to within normal limits with supplements
             before starting treatment

          -  Patients must avoid consumption of grapefruit, pomegranates, starfruit, Seville
             oranges or products containing the juice of each during the entire study and
             preferably 7 days before the first dose of study medications; orange juice is allowed

        Exclusion Criteria:

          -  Another bone marrow malignancy

          -  Another cancer with expected survival of &lt; 2 years

          -  Active viral, bacterial, or fungal infection progressing on current treatment

          -  Clinically significant uncontrolled heart disease and/or recent cardiac event within 6
             months prior to enrollment, such as:

               -  History of angina pectoris, symptomatic pericarditis, or myocardial infarction

               -  Left ventricular ejection fraction (LVEF) &lt; 45% as determined by echocardiogram
                  (ECHO) or multi gated acquisition (MUGA) scan

               -  History or presence of any cardiac arrhythmias, e.g. ventricular,
                  supraventricular, nodal arrhythmias or conduction abnormality; stable atrial
                  fibrillation within 6 months prior to randomization is permitted

               -  Presence of unstable atrial fibrillation (ventricular response rate &gt; 100 beats
                  per minute [bpm]); NOTE: patients with stable atrial fibrillation

               -  Resting heart rate &lt; 50 bpm

               -  Complete left bundle branch block (LBBB), bifascicular block

               -  Congenital long QT syndrome

               -  Any clinically significant ST segment and/or T-wave abnormalities

               -  Corrected QT (QTcF) &gt; 450 msec for males and females using Fridericia's
                  correction on screening electrocardiogram (ECG) by mean value of triplicate ECGs

               -  History of documented congestive heart failure (New York Heart Association
                  functional classification III-IV)

               -  Uncontrolled hypertension defined by a systolic blood pressure (SBP) &gt;= 150 mmHg
                  and/or diastolic blood pressure (DBP) &gt;= 100 mmHg with or without
                  antihypertensive medication; NOTE: initiation or adjustment of antihypertensive
                  medication(s) is allowed prior to screening

               -  Other clinically significant heart disease or vascular disease

          -  Taking medications with risk of prolonging the QT interval or inducing torsade de
             pointes, if such treatment cannot be discontinued or switched to a safe alternative
             medication prior to starting treatment

          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of panobinostat or dexamethasone (e.g. ulcerative disease
             uncontrolled nausea, vomiting, malabsorption syndrome, obstruction, or stomach and/or
             small bowel resection)

          -  Unresolved diarrhea &gt;= Common Terminology Criteria for Adverse Events (CTCAE) grade 2
             or a medical condition associated with chronic diarrhea (such as irritable bowel
             syndrome, inflammatory bowel disease)

          -  Major surgery =&lt; 14 days prior to starting study treatment or who have not recovered
             from side effects to &lt; grade 2 CTCAE

          -  Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)
             not using an effective method of birth control; WOCBP are defined as sexually mature
             women who have not undergone a hysterectomy or who have not been naturally
             postmenopausal for at least 12 consecutive months (i.e. who has had menses anytime in
             the proceeding 12 consecutive months); women of childbearing potential must have a
             negative serum pregnancy test within 24 hrs of receiving the first dose of study
             medication

          -  Male patients whose sexual partners are WOCBP not using effective birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Becker</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela S. Becker</last_name>
      <phone>206-606-7273</phone>
      <email>pbecker@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Pamela S. Becker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2017</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Panobinostat</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

